Search | Clinical Trials Finder

Conditions: Early Breast Cancer
Interventions: Giredestrant, Anastrozole, Palbociclib, Surgery; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: Burbank, California • Laguna Hills, California • San Luis Obispo, California + 7 more

Conditions: Human Papillomavirus Infections
Interventions: Ad26.HPV16, Ad26.HPV18, MVA.HPV16/18, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 11
States / cities: Doral, Florida • Fort Myers, Florida • Miami, Florida + 8 more

Conditions: Eating Behavior
Interventions: Sequential Variety, Simultaneous Variety, Single Food, Small portion, Large Portion; Other
Lead sponsor: Penn State University; Other
Eligibility: 20 Years to 65 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Down Syndrome, Edwards Syndrome
Interventions: Maternal Blood Draw; Other
Lead sponsor: Progenity, Inc.; Industry
Eligibility: 18 Years to 54 Years · Female only
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 10
States / cities: Campbell, California • Long Beach, California • Denver, Colorado + 6 more

Conditions: PTSD
Interventions: Placebo, Paroxetine, Positron Emission Tomography (PET) Imaging; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pain
Interventions: SRP-3D (diethylamide), Placebo; Drug
Lead sponsor: South Rampart Pharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypogonadotropic Hypogonadism
Interventions: Luveris® 75 IU, Luveris® 25 IU, Placebo, Recombinant human follicle stimulating hormone (r-hFSH), Recombinant human chorionic gonadotropin (r-hCG); Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Monomethyl Fumarate 190 Mg, Diroximel Fumarate 462 mg; Drug
Lead sponsor: Banner Life Sciences LLC; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Contraceptive Use, Unintended Pregnancy
Interventions: Reproductive Life Planning (RLP), Contraceptive Action Planning, Contraception information; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Healthy
Interventions: Metformin, Canagliflozin (JNJ-28431754); Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Contraception
Interventions: Ulipristal Acetate, Combined Oral Contraceptive Pill; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: New York, New York

Conditions: Bioavailability and AUC
Interventions: Removal from study. In case of adverse event, subject treated for the AE., removal from study; Other
Lead sponsor: Vireo Systems, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Raritan, New Jersey

Conditions: Iron Deficiency Anemia of Pregnancy, Iron Malabsorption
Interventions: Iron dextran, Ferrous sulfate 325mg; Drug
Lead sponsor: Indiana University; Other
Eligibility: Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Indianapolis, Indiana • St Louis, Missouri

Conditions: Metastatic Breast Cancer, Neoplasms, Breast
Interventions: Investigational Cancer Drug; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 30
States / cities: Chula Vista, California • Los Angeles, California • Poway, California + 24 more

Conditions: Breast Cancer, Overweight or Obesity
Interventions: Contrave, Behavioral Weight Loss; Drug · Behavioral
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Urinary Incontinence
Interventions: Office evaluation, UDS; Other
Lead sponsor: Carelon Research; Other
Eligibility: 21 Years and older · Female only
Enrollment: 630 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 10
States / cities: Birmingham, Alabama • San Diego, California • Maywood, Illinois + 7 more

Conditions: Drug Induced Constipation
Interventions: NKTR-118, Rifampin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Post-Traumatic Stress Disorder
Interventions: Brexanolone Injection [Zulresso]; Drug
Lead sponsor: Donald Jeffrey Newport; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Lung Disease, Pneumothorax, Tuberous Sclerosis, Lymphangioleiomyomatosis
Interventions: Toshibia Aquilion One CT; Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 16 Years to 100 Years
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Parkinson's Disease, Aging
Interventions: Respiratory resistive load on inhalation, Fluoroscopic swallowing evaluation; Other
Lead sponsor: University of Florida; Other
Eligibility: 45 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Crohn's Disease
Interventions: GSK1605786 ChemoCentryx: formulation A, GSK1605786 GSK: formulation B, GSK1605786 GSK direct-fill: formulation C, GSK1605786 GSK modified-process: formulation D, GSK1605786 GSK tablet: formulation E; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Respiratory Syncytial Virus
Interventions: mRNA-1345, Placebo; Biological · Drug
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 12 Months to 79 Years
Enrollment: 651 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 31
States / cities: La Mesa, California • West Hollywood, California • DeLand, Florida + 28 more

Conditions: Acellular Pertussis, Diphtheria, Tetanus
Interventions: Boostrix™, ADACEL®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 19 Years to 64 Years
Enrollment: 2,337 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 42
States / cities: Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 36 more

Conditions: Physical Activity
Interventions: Intervention, Comparison; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years and older · Female only
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Columbia, South Carolina

Search by objective public record fields.

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Combined Effects of Variety and Portion Size on Meal Intake of Women

Non-Invasive Screening for Fetal Aneuploidy

Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder

Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA)

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects

MyNewOptions: An Online Study of Reproductive Life Planning and Contraceptive Action Planning

A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers

Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation

The Objective of This Study Was to Compare and Quantify the Bioavailability of Citrulline Byproducts in Blood Samples and in Urine Samples After a Single Dose of the Assigned Dietary Supplement. The Treatment Arms Containing the Following Molecules: Citrulline HCL and L-Citrulline,

Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial

Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.

Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study

Value of Urodynamic Evaluation

Study in Healthy Volunteers to Investigate the Effects of Rifampin on the Pharmacokinetics of NKTR-118

An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder

Study of the Disease Process of Lymphangioleiomyomatosis

Respiratory Load Magnitude Estimation in PD

A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects

A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years

Together Everyone Achieves More (TEAM) Trial